• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A …<CHEM>… wherein R<1> and R<2> each is alkyl, alkenyl or alkoxyalkyl, wherein R<3> and R<4> each is alkyl, wherein benzene ring A is unsubstituted or bears one or more additional substituents selected from halogeno, cyano, nitro, trifluoromethyl and alkyl, or bears the substituent =N-O-N= attached to the 5-and 6-positions, wherein Ar is phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl which is unsubstituted or which bears one or more substituents, or Ar is a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur, which ring is saturated or unsaturated, which ring is unsubstituted or bears one or more substituents and which ring may also be fused to a benzene ring, wherein p is 0 or 1, wherein X is -O- or -S-, and wherein Y is straight-or branched-chain alkylene or alkenylene each of 2 to 12 carbon atoms which may optionally be interrupted by one or two groups selected from oxygen, sulphur, imino, substituted imino, phenylene, substituted phenylene, pyridylene, cycloalkylene, 1,4-piperazinediyl, 1,4-piperidinediyl and amido groups, or an acid-addition salt thereof, processes for their manufacture and pharmaceutical compositions containing them. The compounds possess either beta-adrenergic blocking or calcium ion slow channel blocking properties, or both such properties, and may be used in the treatment of hypertension.
    公开号:SU1590041A3
    申请号:SU864027023
    申请日:1986-02-10
    公开日:1990-08-30
    发明作者:Брайан Харгривс Родни；Джозеф Маклафлин Бернард；Деннет Миллс Стюарт
    申请人:Империал Кемикал Индастриз Пл.С.(Фирма)；
    IPC主号:
    专利说明:

    one
    (21) 4027023 / 23-04
    (22) 02/10/86
    (31) 8503425
    (32) 11..02.85
    (33) GB
    (46) 08/30/90. Bul Number 32
    (71) Imperial Chemical Industries PL.S. (GB)
    (72) Rodney Brian Hargreaves, Bernard Joseph McLaughlin, and Stuart Dennett Mills (GB)
    (53) .547.022.1.07 (088.8)
    (56) Japanese Jounal of Pharmacolosv
    1987.0-46.
    Japanese Jounal of Pharmacoloev
    1988 P-377.
    European patent No. 0167371, cl. C 07 D 211/90, 1986.
    Patent of the USSR No. 1342413, cl. C 07 D 211/82, 1984. (54) METHOD FOR OBTAINING 1,4-DIHYDROPYRIDINE DERIVATIVES
    (57) The invention relates to heterocyclic compounds, in particular, a process for the preparation of 1,4-dihydropyridine derivatives of the general formula X-NH-CHj-CH Son} -CE, -OAg, where X is a group of the formula -Y-0-C CH -CH CA-CH C CH-C OC (O) OR-, C (CH 3) -NH-C (CH 3) (0) OR, J; R - SNZ or.; A-CN or NO; Ag - phenyl | may be substituted by C1, NGj, CN, lower alcohis, or amyloxy group J; Y —fCHj —C (CH3) 2-; with m 2 or 3, possessing antihypertensive and β-adrenergic activity, which can be used in medicine. The goal is to create new active substances of the specified class. The synthesis is carried out by the interaction of an amine of the general formula X-MH, where X is indicated above, with an epoxide of the formula CHjO-Ar, where Ar is indicated in greater detail. The new compounds lower the mean arterial pressure by 20–42 mm Hg, and at the same time show l-adrenergic activity without toxicity at the applied concentrations of 10 mg / kg. 3 tab.
    about
    (L
    sd
    ;about
    The invention relates to the chemistry of heterocyclic compounds, in particular to 1,4-dihydropyrvidine derivatives having antihypertensive and β-adrenergic activity, which may be used in medicine.
    The purpose of the invention is to create, on the basis of known methods, a method for the preparation of 1,4-dihydropyri-, dine derivatives having simultaneously / 5-allergenic and antihypertensive activity with low toxicity.
    The invention is illustrated by the following examples.
    Example 1. A mixture of dimethyl-4-G 2- (4-aminobutoxy) -5-nitrophenyl.} - 1,4-dihydro-2,6-dimethylpyridin-3, 5-dicarboxylate (0.35 g), phenylglycidyl ether (0.12 g) and isophopanol a (10 ml) are heated at reflux for 3.5 hours and then evaporated to dryness, and the resulting residue is purified by chromatography with an instant evaporation (/ I
    It is placed on a silica gel column (Megsk 9385) using a 80: 20: 3 mixture (volume-volume-volume) of ethyl acetate, methanol and concentrated aqueous ammonia as eluent. The product obtained is crystallized from a mixture of ethyl acetate and petroleum ether (bp), and as a result, dimethyl-1,4-dihydro-4-2.-4- (2-ca-1o si-3-phenoxypropylamino) is obtained. -5- -nitrophenyl-2, B.-dimethylpyridine-3,5-di-carboxylate, so pl. 117-120 s (reference compound - example 15).
    Dimethylpyridine 3,5-dicarboxylate, tS cat, ory is used as a starting material, is obtained as follows.
    A stirred mixture of 5-nitrosal-: cilaldehyde (8.36 g), carbonate of carbonate — LIA (11.04 g) of potassium iodide (0.2 g), M- (4-bromobutyl) phthalimide (13.6-g) and dimethylformamide (120 ml) is heated to 100 ° C for 48 h, and then ohridine-3, 5-dicarboxylate, so pl. 119 - 123 C.
    A mixture of the obtained compound (1.8 g) hydrazine hydrate (1.8 ml) and ethanol (35 ml) is heated at reflux for 18 hours, heated at ambient temperature for 18 hours and then filtered. The resulting filtrate is quenched to dryness and the residue is crystallized from ethanol. Dimethyl-4- 2- (4-aminobutoxy) -5-nitrophenyl} -1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate is obtained, m.p. 200-202 C.
    Example 2. The procedure of Example 3 was repeated using the appropriate 4- (2-amino-hydrocarbyloxyphenyl) pyridine and the corresponding epoxide as starting materials, resulting in the compounds described in Table 2. 1. If the compounds do not crystallize and therefore cannot
    Clutter to room temperature. Up to 25 ° C, melt a saturated aqueous solution of sodium chloride (1200 ml) and ethyl acetate (300 ml) and the mixture is shaken and filtered, and the solid residue is left. The layers of the filtrate are separated., The SO aqueous layer is extracted with ethyl acetate (200 ml) and the combined ethyl acetate solution is washed three times with sesh-. This is confirmed by elemental analysis, mass spectroscopy and proton magnetic resonance spectroscopy.
    Example 3. The process described in Example 1 was repeated, but the corresponding material was used to substitute (for SHO ml each time), respectively, over 35% (8) -phenylglycidyl simple
    ether and thus obtained the compounds described in table. 2
    magnesium sulfate and evaporated to the ear. The combined residue and the remaining solid are crystallized from methanol and thus 5-nitro-2- - (4-phthalimidobutoxy) benzaldehyde is obtained, m.p. 145-148 C.
    A stirred mixture of the indicated aldehyde (5.68 g) of methyl 3-amino-nitro (1.92 g), methylacetoacetate (1.79 g) and isopropanol (30 ml) is heated at the boiling point: under reflux for 40 h, cooled, to ambient temperature and the liquid portion is decanted from the precipitated resin. The resin is transferred with diethyl ether and the resulting mixture is filtered, and the liquid is stored at room temperature for 18 hours and then filtered. The combined solid residues crystallize from isoprog panol to give dimethyl-1,4-dihydro-2,6-dimethyl 4 -2 - (4-β-naphmidobutoxy) -5-nitrophenyl} - pi
    Ridin-3,5-dicarboxylate, so pl. 119 - 123 C.
    A mixture of the obtained compound (1.8 g) hydrazine hydrate (1.8 ml) and ethanol (35 ml) is heated at reflux for 18 hours, heated at ambient temperature for 18 hours and then filtered. The resulting filtrate is quenched to dryness and the residue is crystallized from ethanol. Dimethyl-4- 2- (4-aminobutoxy) -5-nitrophenyl} -1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate is obtained, m.p. 200-202 C.
    Example 2. The procedure of Example 3 was repeated using the appropriate 4- (2-amino-hydrocarbyloxyphenyl) pyridine and the corresponding epoxide as starting materials, resulting in the compounds described in Table 2. 1. If the compounds do not crystallize and therefore cannot
    to characterize the floating temperatures
    The laziness, structure is confirmed according to the elemental analysis, mass spectroscopy and proton magnetic resonance spectroscopy.
    Example 3. The process described in Example 1 was repeated, but the appropriately substituted (8) -phenylglycidyl simple was used as the starting material.

    0
    ether and thus obtained the compounds described in table. 2
    All compounds had (S) configuration with the specified group SNON-,
    Methods and results of pharmacological testing. Each rat in a group of 4, 5, or 6 females of the Okotnoto spontaneously hypertensive line of about 5 months of age and weighing between 200 and 250 g was anesthetized with halothane (2%) and the carotid artery was removed through an incision below the neck. A constant catheter, filled with a heparinized physiologist, is implanted into the artery and turned out from the back of the neck with 50 tons of solution (50 units per 1 ml). Animals are left for 24 hours to recover from surgery and then restricted to. plastic test tubes with open ends. The pressure sensor is then connected to the catheter as well as to the recording equipment so as to ensure continuous recording of the heart rate and blood pressure.
    The test compound is administered to each animal as a single dose (10 mg per 1 kg of body weight) oral dose dissolved in 1 ml of 5: 4: 1 vol. mixtures of polyethylene glycol, physiological solution and ethanol. Blood pressure is recorded before dosing and after 1.3 and 5 hours after it.
    The maximum decrease (compared to the predosing value) of mean arterial pressure (MAP) is recorded over a 5-hour observation period. A compound is active as an antihypertensive, if this decrease is at least 20 mm Hg.
    Slaughter rats. Each rat in a group of 4 females of the normotensive line of Wistor weighing approximately 250 g was anaesthetized with a galotine (2%) and a tracheotomy cannula was inserted. Then the rat is quickly killed through the eye socket by means of a 14 gauge steel piercing rod. Then the rat is immediately transferred to artificial respiration using a Palmer pump with a 3: 2 mixture of vol. nitrogen and oxygen with a stroke volume of 3 ml and 53 cycles per i. min.
    The first strap vein is cannulated for - drug administration and the left common carotid artery is cannulated and connected to a pressure transducer, which is also connected to a recording equipment.
    increase in heart rate by 50 beats per .1 min, read from the curve. If the compound has beta-adrenergic blocking activity, the dose of isoprenaline, which is necessary to obtain an increase in the heart rate of 50 beats, will be higher than the dose in control.
    Experimental experiment on an animal that did not receive the drug.
    The compound is believed to be in -. is active as a beta for the energy blocking agent
    15 if its coefficient is at least 15.
    The results obtained using certain alkanolamine derivatives are given in table. 3
    20 All compounds tested when receiving spontaneously hypertensive rats and the results recorded. Only a few compounds were tested when receiving a slaughtered rat, if not a single result was recorded, this means that the compound was not tested with this preparation.
    All compounds in this table. 3 have (S) -configuration at specified
    30 group -SHONE-.
    Preferred proposed compounds in which Y is a branched chain alkylene group (Table 3) are more active against the test with slaughtered rats (i.e., as adrenergic beta locators) compared with the known compounds.
    With doses of a derivative dihydropinium in order to carry out continuous- ". readin which have effective
    recording of heart rate and blood pressure. Both. the vagus nerve is also dissected.
    Then build the curve of the dependence of the dose-effect on heart rate in relation to isoprenaline, using dosage levels of 0.003; 0.01; 0.03 and 0.1 μg per 1 kg of body weight of isoprenaline. The test compound is then administered intravenously for 3 minutes in 0.25 ml of a 5: 4:: 1 (v) solution. A mixture of polyethylene glycol, physiological solution and ethanol containing 1 mg per 1 kg of the body weight of the compound. 30 minutes after dosing, the dose-effect versus heart rate curve is again re-constructed for isoprenaline. The doses of isoprenaline required for
    50
    antihypertensive effect on rats or dogs, no symptoms of toxicity are observed.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining 1,4-dihydropyridine derivatives of the general formula
     OY-HH-CHjCHCHiOAr
    he .
    55 "t
    BUT
    Ag methyl or ethyl; a substituent selected from a cyano or nitro group; phenyl, not necessarily substituted by chlorine, nitro.
    increase in heart rate by 50 beats per .1 min, read from the curve. If the compound has beta-adrenergic blocking activity, the dose of isoprenaline, necessary to obtain an increase in heart rate by 50 beats, will be higher than the dose in control.
    Experimental experiment on an animal that did not receive the drug.
    The compound is believed to be in -. . is active as a beta for the energy blocking agent
    5 if its coefficient is at least 15.
    The results obtained using certain alkanolamine derivatives are given in table. 3
    0 All compounds were tested in spontaneously hypertensive rats and the results were recorded. Only a few compounds were tested when a rat was slaughtered, if not a single result was registered, it means that the compound was not tested with this preparation.
    All compounds in this table. 3 have (S) -configuration at specified
    0 group -SHONE-.
    Preferred proposed compounds in which Y is a branched chain alkylene group (Table 3) are more active against the test with slaughtered rats (i.e., as adrenergic beta-locators) compared to known compounds, .
    At doses of the derivative dihydropia antihypertensive effect on rats or dogs, no symptoms of toxicity are observed.
    Invention Formula
    The method of obtaining 1,4-dihydropyridine derivatives of the general formula
    50
     OY-HH-CHjCHCHiOAr
    he .
    "T
    BUT
    Ag methyl or ethyl; a substituent selected from a cyano or nitro group; phenyl, not necessarily substituted by chlorine, nitro.
    cyano, lower alkoxy or
    amyloxy; Y - group of formula - (СН ,,) ,,
    -C (CH3) 2, where ha is 2 or 3, compared with the general formula
    BUT
    p -,., LO-Y-NH,
    J looc ug coofij
    HjC CHj
    H
    virO-T-: NH-
    V CHZ H
    Me-CH, CH, C (CH,), Fensch Oil
    Me- (CK) C (CEy), 2-Methoxyphenyl 124 - 127
    SNS
    C-NHCH CHOHCH O -Ag
    sn,
    where R, A, Y have the indicated meanings, are reacted with an epoxide of the general formula
    CH CH-SNGO-AG
    where Ag has the specified value.
    Table 1
    CH CHOHCHzOAr
    table 2
    sn,
    1590041
    10 Table 3
    类似技术:
    公开号 | 公开日 | 专利标题
    US5041653A|1991-08-20|Substituted benzamide radiosensitizers
    DE1957706C3|1978-06-29|Nuclear-substituted 3-phenoxy-1-phenoxyalkylamino-propan-2-ols and drugs based on them
    CS244423B2|1986-07-17|Method of substituted 1,2-diaminocyclobuten-3,4-dions production
    CH616677A5|1980-04-15|
    CA2174969C|2005-05-17|Short-acting dihydropyridines
    JP2651043B2|1997-09-10|Diphenylmethylpiperazine derivative
    SU1241986A3|1986-06-30|Method of producing benzamide derivatives,hydrochlorides thereof or optical isomers
    IE51551B1|1987-01-07|Isoquinoline derivatives,process for their preparation and pharmaceutical formulations containing them and their use
    SU1590041A3|1990-08-30|Method of producing derivatives of 1,4-dihydropyridine
    PL167302B1|1995-08-31|Method of obtaining novel 1r-cis, 1&#39;r-cis-2,2&#39;-|-bis-(1,2,3,4 tetrahydro-6,7-dimethoxy-2-methyl-1-veratryloisoquinolinic salts
    JP3083544B2|2000-09-04|Drugs to prevent or treat heart disease
    US3940387A|1976-02-24|Yohimbine derivatives, process for their preparation and their applications
    PL137716B1|1986-07-31|Process for preparing derivatives of imidazoline
    US4551453A|1985-11-05|2-|- and 2-|-phthalimidines
    EP0273744A2|1988-07-06|Centrally-acting muscle relaxants
    US4173636A|1979-11-06|Decahydroquinolines, pharmaceutical compositions and methods of use
    KR860000103B1|1986-02-19|Process for preparing 3&#39;-substituted-5&#39;-|-1&#39;,2&#39;4&#39;-triazoles
    RU2280034C2|2006-07-20|Compounds, method for their preparing, pharmaceutical composition, selective antagonists of 5-ht2a -receptor
    EP0076952A1|1983-04-20|N-acyl-3-|piperazin-1-yl)-sydnonimine compound, process for production thereof, and use thereof
    SU1398771A3|1988-06-15|Method of producing substituted benzamides
    US3758485A|1973-09-11|Furan carboxylic acid pyridylamides
    US3555019A|1971-01-12|-1,4-oxazine derivatives
    JPH07603B2|1995-01-11|Isoquinoline sulfonamide derivative
    EP0869957B1|2002-03-13|3|-pyridazinone derivatives and pharmaceutical compositions containing these compounds
    KR900001198B1|1990-02-28|2,5-disubstituted-4|-pytimidones having histamine h2-receptor antigonist activty
    同族专利:
    公开号 | 公开日
    DK66186D0|1986-02-11|
    PL153857B1|1991-06-28|
    NO860465L|1986-08-12|
    DD250533A5|1987-10-14|
    PL149828B1|1990-03-31|
    JPH0819100B2|1996-02-28|
    GB8503425D0|1985-03-13|
    PL265252A1|1988-06-09|
    ES8802496A1|1988-07-01|
    KR860006443A|1986-09-11|
    ES8802139A1|1988-04-01|
    AU5339486A|1986-08-14|
    EP0194751A1|1986-09-17|
    FI860621A0|1986-02-11|
    HUT40415A|1986-12-28|
    PT82008B|1988-07-01|
    DK66186A|1986-08-12|
    PH22683A|1988-11-14|
    HU196179B|1988-10-28|
    EP0194751B1|1992-04-15|
    PT82008A|1986-03-01|
    PL257902A1|1988-03-03|
    CS273172B2|1991-03-12|
    GB8602704D0|1986-03-12|
    ES551844A0|1988-04-01|
    CS91186A2|1990-07-12|
    ZA86967B|1986-11-26|
    FI860621A|1986-08-12|
    NZ215083A|1989-10-27|
    DE3684803D1|1992-05-21|
    ES557630A0|1988-07-01|
    JPS61233669A|1986-10-17|
    GR860369B|1986-06-02|
    US4873254A|1989-10-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2228363A1|1972-06-10|1974-01-03|Bayer Ag|1,4-DIHYDROPYRIDINE, METHOD FOR MANUFACTURING AND USE AS A MEDICINAL PRODUCT|
    GB1409865A|1973-02-13|1975-10-15|Science Union & Cie|Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them|
    US4500527A|1983-06-22|1985-02-19|Usv Pharmaceutical Corporation|Antihypertensive 4[-oxyiminomethyl phenyl]-1,4-dihydropyridines|
    JPH0123463B2|1984-06-28|1989-05-02|Yamanouchi Pharma Co Ltd|JPH0123463B2|1984-06-28|1989-05-02|Yamanouchi Pharma Co Ltd|
    EP0276552A1|1986-12-08|1988-08-03|Yamanouchi Pharmaceutical Co. Ltd.|1,4-dihydropyridine derivatives and their production|
    GB9102031D0|1991-01-30|1991-03-13|Fujisawa Pharmaceutical Co|Dihydropyridine compounds,and process for their preparation|
    EP1108710A4|1998-07-23|2001-11-21|Chen Ing Jun|Guaiacoxypropanolamines with alpha/beta-adrenergic blocking activity|
    CN101917980B|2007-11-01|2013-12-11|奥克塞拉有限公司|Amine derivative compounds for treating ophthalmic diseases and disorders|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB858503425A|GB8503425D0|1985-02-11|1985-02-11|Alkanolamine derivatives|
    [返回顶部]